Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
about
Therapeutic interventions for disease progression in Huntington's diseaseEvidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of NeurologyBioactive lipids in schizophrenia.Fatty acids and neuropsychiatric disorders.Cell Therapy Strategies vs. Paracrine Effect in Huntington's Disease.Therapeutic Strategies in Huntington's DiseaseTracking motor impairments in the progression of Huntington's disease.Omega-3 fatty acids in ADHD and related neurodevelopmental disorders.Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: a review of clinical investigations.Monitoring Huntington's disease progression through preclinical and early stagesTardive dyskinesia and essential fatty acids.A systematic review of the treatment studies in Huntington's disease since 1990.Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications.Huntington's disease: progress and potential in the field.Role of Lipids in Brain Injury and Diseases.Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.Neuroprotection for Huntington's disease: ready, set, slowAltered lipid metabolism in brain injury and disorders.Emerging drug therapies in Huntington's disease.Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.Molecular mechanisms and potential therapeutical targets in Huntington's disease.Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.Pharmacologic approaches to the treatment of Huntington's disease.Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.Neuroprotective effects of psychotropic drugs in Huntington's diseaseThe most appropriate primary outcomes to design clinical trials on Huntington's disease: meta-analyses of cohort studies and randomized placebo-controlled trials.Animal models of Huntington's disease for translation to the clinic: best practices.Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts.Revealing disease-associated pathways by network integration of untargeted metabolomics.Rate of change in early Huntington's disease: a clinicometric analysis.Nucleic Acid-Based Therapy Approaches for Huntington's DiseaseTreatment of huntington diseaseMouse models of Huntington disease: variations on a theme.Copy number variation, eicosapentaenoic acid and neurological disorders.Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease.Essential fatty acid-rich diets protect against striatal oxidative damage induced by quinolinic acid in rats.Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.Design optimization for clinical trials in early-stage manifest Huntington's disease.
P2860
Q24239973-4E9C5F9E-88F2-4C2C-8A6C-73852B9E9444Q24621818-2459240A-3D86-45CA-BAC5-925BAB31AD0FQ33246888-EFC5A243-92AA-498B-B2DE-0334809D264EQ33330516-282574B7-2B4F-4951-ABBF-8A4DB2514FBFQ33734410-B434AF4D-9F82-49EA-9F82-2B68D9180E28Q33790829-593AC811-D2F5-4CAF-854E-C84B421138B4Q34449476-953EAB9D-F16E-4498-B6FA-0D6C82B07A8EQ34538615-A36F2974-05BD-49BF-96E2-3E933A98F16AQ34583573-97C20FD5-A133-4A23-91E9-BB9C02F5C45AQ36459201-7FDC6756-30E7-49FC-8B23-6528C96DA710Q36508056-07A8AEC4-E6DE-4C20-807D-910961B3E8BBQ36719669-D3195589-8AA4-4C07-B296-268BC997C30EQ36957089-7EA3A1D4-510C-4A31-9F38-9650127253BEQ37003956-2F76104F-3EC6-4AC5-9C54-DE75D6BBB35CQ37016096-91953072-DB95-4126-805F-A97BF02C5C23Q37051065-5FA853E3-2CF9-47F2-A2B0-813D76687518Q37093708-A109F1BB-A4EA-4E30-891F-F62AA7824B2EQ37131243-012EFDCC-0FD1-400D-9848-372255C8D430Q37254313-15577FF4-ABBA-44BB-8915-1B47F5C34F35Q37488273-D9F6EE9C-3BD9-429C-9DBC-AD1F015B0B61Q37580731-30504E4B-1EDE-4E95-A60A-F29AF557B129Q37776087-3A7CEAE6-5337-4E0C-B9C0-D58C32DBC849Q37866383-5A3C81EA-BD19-4A36-98F6-31D88BD49842Q37945478-5E51CC19-A5C9-49AA-9EF8-D10330713221Q38022265-6784D781-B10F-44B2-86ED-3B05BCEE363FQ38163877-887507B1-1D69-4201-9739-3D9DAC0E1664Q38202178-C43C699F-54F1-4AF6-900A-48D44DD22CEDQ38248687-4FDF367B-1AE9-4A81-80E9-B9BA216A5A42Q38792714-863446BA-6C0B-4B11-BBBE-D282D7C9BC94Q39538215-9081E3B5-3F3A-4878-9752-58D61BC3E7E7Q39685633-70710C11-7AA8-4F0D-B73E-DC92EC767FFCQ40582623-888FC883-0A05-41F6-AD8E-B5406B7E4BD2Q42052656-D42CA9DC-B3BF-4CE1-9AE3-15457566FB97Q42155772-72273A73-BE70-493C-8946-3FB21C493087Q42743618-431D4937-02C7-4102-87A2-1B9017DB2114Q45289087-A043A392-58C4-4662-BC1A-0C7780A1BDA5Q45291055-C74AF527-A4F3-4799-B32D-84F6F1985BF1Q45293662-96D721EC-3820-4A87-9834-E27F63AF55F7Q45294777-788E3039-8E66-4BB6-986A-12167EBFB7DDQ45304194-93D0F1BC-982F-4FCC-A003-F7935F93A39E
P2860
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
@en
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
@nl
type
label
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
@en
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
@nl
prefLabel
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
@en
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
@nl
P2093
P1433
P1476
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
@en
P2093
Greenamyre JT
Horrobin DF
Leavitt BR
Rosenblatt A
P304
P356
10.1212/01.WNL.0000169025.09670.6D
P407
P577
2005-07-01T00:00:00Z